DrugPatentWatch Database Preview
« Back to Dashboard
Summary for Patent: 7,291,324
|Title:||Method of bowel cleansing|
|Abstract:||Stimulant laxative in combination with an osmotic laxative produces safe and effective bowel and colon cleansing with a reduced volume of liquid input. Administering to a patient an oral stimulant laxative, such as bisacodyl, followed, after a biologically determined interval, by a reduced volume of a PEG in water solution cleanses the bowels and colon in preparation for diagnostic colonoscopy, without the profuse uncontrollable diarrhea that typically follows either ingestion of large volume isotonic ravages, or smaller volume hypertonic lavages.|
|Inventor(s):||Dennett, Jr.; Edmund V. (Walpole, MA), Raleigh, Jr.; Robert M. (Braintree, MA), Cleveland; Mark V B. (Duxbury, MA), Pelham; Russell W. (Duxbury, MA)|
|Assignee:||Braintree Laboratories Inc. (Braintree, MA)|
1. A method for cleansing bowels and colon of a mammal, the method consisting essentially of: a) orally administering to the mammal from about 5 mg to about 40 mg of
bisacodyl; b) waiting until the bisacodyl produces a bowel movement, the bowel movement occurring within 6 hours; c) orally administering to the mammal from about 50 g to about 400 g of polyethylene glycol (PEG) in from about 1.5 L to about 2.5 L of an
isotonic solution following the bowel movement; and d) thereafter allowing the mammal to evacuate the bowels and colon; e) the method optionally including the further step of administering a clear liquid to the mammal after administration of the
bisacodyl; whereby the colon is adequately cleansed to permit diagnostic testing or surgery.
2. The method of claim 1, wherein the amount of the isotonic solution is about 2 L.
3. The method of claim 1, wherein the amount of bisacodyl is from about 10 mg to about 20 mg.
4. The method of claim 1, whereby preparation time of the bowels and colon and adverse symptoms in the mammal are diminished.
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally: